Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (SPHDF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Santhera Pharmaceuticals Holding AG (SPHDF), covering cash flow, earnings, and balance sheets.
Santhera Pharmaceuticals Holding AG (SPHDF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Santhera Pharmaceuticals Holding AG SPHDF financial performance.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $25.003M | $14.11M | $118.11M | $54.33M |
| Cost of Revenue | $10.66M | $5.21M | $1.94M | $713903.00 |
| Gross Profit | $14.34M | $8.90M | $116.16M | $53.62M |
| Gross Profit Ratio | $0.57 | $0.63 | $0.98 | $0.99 |
| R&D Expenses | $12.70M | $13.77M | $10.60M | $4.88M |
| SG&A Expenses | $17.23M | $12.93M | $21.41M | $10.03M |
| Operating Expenses | $29.93M | $26.64M | $32.02M | $3.90M |
| Total Costs & Expenses | -$40.59M | $31.86M | $33.96M | $4.61M |
| Interest Income | $11.14M | $0.00 | $0.00 | $6.99M |
| Interest Expense | $16.14M | $0.00 | $30.12M | $0.00 |
| Depreciation & Amortization | $2.87M | $2.77M | $1.44M | $423863.00 |
| EBITDA | -$1.40M | -$14.97M | $110.17M | $39.46M |
| EBITDA Ratio | -$0.06 | -$1.06 | $0.72 | $0.73 |
| Operating Income | -$15.59M | -$17.74M | $84.15M | $39.04M |
| Operating Income Ratio | -$0.62 | -$1.26 | $0.71 | $0.72 |
| Other Income/Expenses (Net) | -$10.99M | $2.65M | $8.78M | -$5.96M |
| Income Before Tax | -$26.57M | -$15.09M | $92.93M | $42.74M |
| Income Before Tax Ratio | -$1.06 | -$1.07 | $0.79 | $0.79 |
| Income Tax Expense | $138000.00 | $174000.00 | $146092.00 | $66638.00 |
| Net Income | -$26.71M | -$15.26M | $92.78M | $42.67M |
| Net Income Ratio | -$1.07 | -$1.08 | $0.79 | $0.79 |
| EPS | -$2.34 | -$1.35 | $8.31 | $3.99 |
| Diluted EPS | -$2.34 | -$1.35 | $8.31 | $3.99 |
| Weighted Avg Shares Outstanding | $0.00 | $11.34M | $11.16M | $10.69M |
| Weighted Avg Shares Outstanding (Diluted) | $0.00 | $11.34M | $11.16M | $10.69M |
The company's financials show resilient growth, with revenue advancing from $54.33M in Q3 2023 to $25.003M in Q4 2024. Gross profit remained healthy with margins at 57% in Q4 2024 compared to 99% in Q3 2023. Operating income hit -$15.59M last quarter, sustaining a consistent -62% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.40M. Net income dropped to -$26.71M, while earnings per share reached -$2.34. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan